Xynomic Pharma, a US-Shanghai in-licensing company, has dosed the first South Korean patient as part of the company’s global pivotal Phase III trial of abexinostat, a novel histone deacetylase (HDAC) inhibitor. Xynomic has already started the US arm of the global trial. The company expects to begin similar trials in Europe and China in the first half of 2019. Abexinostat is being tested in combination with pazopanib as a first- or second-line treatment for renal cell carcinoma (RCC). In September 2018, Xynomic completed a reverse merger with Bison Capital Acquisition at a $450 million valuation.
Source: China Biotoday
